Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy

被引：1
|
作者：
Jensen, B. V.
Schou, J. V.
Johannesen, H. H.
Christensen, I. J.
Nielsen, D.
Johansen, J. S.
Hogdall, E. V.
Larsen, O.
Yilmaz, M.
Pfeiffer, P.
机构：
[1] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Radiol, DK-2730 Herlev, Denmark
[4] Univ Copenhagen, Finsen Inst, Copenhagen, Denmark
[5] Univ Copenhagen, Herlev Hosp, Dept Oncol, Copenhagen, Denmark
[6] Univ Copenhagen, Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark
[7] Aalborg Hosp, Dept Oncol, Aalborg, Denmark
[8] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3573
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan
    Gonzalez-Baron, M.
    Blanco, M.
    Feliu, J.
    Gomez, C.
    Casado, E.
    Castro, J.
    Belda-Iniesta, C.
    Garrido, M.
    Aguayo, C.
    Campos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN
    Barbosa, Caroline
    Sousa, Romulado
    Sabbaga, Jorge
    Cotti, Guilherme
    Saragiotto, Daniel
    Hoff, Paulo
    ANNALS OF ONCOLOGY, 2011, 22 : v103 - v103
  • [3] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04): : 337 - 345
  • [4] The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients
    Sohn, Byeong Seok
    Kim, Tae Won
    Lee, Jae-Lyun
    Ryu, Min-Hee
    Chang, Heung Moon
    Kang, Yoon-Koo
    Park, Hyo Suk
    Na, Young-Soon
    Jang, Se Jin
    Kim, Jin Cheon
    Lee, Jung Shin
    ONCOLOGY, 2009, 77 (3-4) : 224 - 230
  • [5] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
  • [6] Therapy with cetuximab and irinotecan in refractory metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (9): : 497 - 498
  • [7] Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients
    Bajetta, E
    Beretta, E
    Di Bartolomeo, M
    Cortinovis, D
    Ferrario, E
    Dognini, G
    Toffolatti, L
    Buzzoni, R
    ONCOLOGY, 2004, 66 (02) : 132 - 137
  • [8] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)
    Amoroso, Vito
    Ferrari, Vittorio
    Valcamonico, Francesca
    Vassalli, Lucia
    Simoncini, Edda
    Grisanti, Salvatore
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63
  • [10] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
12345